Bharat Serums and Vaccines Limited

Bharat Serums and Vaccines Limited, based in India, specializes in developing and manufacturing biopharmaceutical products, focusing on women's health and critical care, leveraging advanced research and innovative solutions for complex medical conditions. Bharat Serums and Vaccines Limited (BSV) is a Mumbai-based pharmaceutical company founded in 1971, providing specialized healthcare products. In July 2024, it was fully acquired by Mankind Pharma Ltd. from Advent International for INR 136.

3 billion. The company has completed 5 deals, with its latest funding round being an Add-on Trade Sale. The current CEO is Sanjiv Navangul, who has significant experience in the pharmaceutical industry. Bharat Serums and Vaccines Limited (BSV) specializes in a diverse range of pharmaceutical and biopharmaceutical products, primarily focused on women's health, critical care, and Assisted Reproductive Technology (ART).

The company offers innovative treatments for infertility, reproductive health issues, and complex medical conditions, including Rh incompatibility, endometriosis, and post-partum hemorrhage. Notable products include the first generic biological High Pure HMG in India and recombinant offerings like FSH and HCG. BSV serves a global customer base, including healthcare providers and hospitals in India, Southeast Asia, and select regions in Europe, supported by a dedicated Research & Development center in Mumbai. In the most recent fiscal year, BSV reported a revenue of INR 124,713,426.

50, with an EBITDA of INR 22,546,265. 30. The company's revenue is generated through direct sales to healthcare institutions and partnerships with distributors, primarily driven by flagship products such as the Biotech Anti-Rho(D) Monoclonal Antibody and innovative formulations like the Propofol Emulsion. In July 2024, Bharat Serums and Vaccines Limited was acquired by Mankind Pharma Ltd.

, which aims to strengthen its presence in the Indian women’s health and fertility drug market through this acquisition. Mankind Pharma plans to leverage BSV's R&D capabilities to access high-barrier products in critical care. The funding from this acquisition will be utilized to support the launch of new products aimed at addressing unmet medical needs and expanding BSV's reach into new markets, with a particular focus on enhancing R&D efforts and exploring strategic collaborations.